Forward Citations = 23

Loading Chart...

3 inventors (with patents filed for the assignee):

J Curtis Nickel (2 out of 3 patents)

J Thomas Buckley (1 out of 4 patents)

James Thomas Buckley (1 out of 4 patents)

4 patents: Sort by Forward Citations

1. 10654900 - Method for treating prostatitis utilizing the pore-forming protein proaerolysin PRX302 (2020-05-19),

2. 9950029 - Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins (2018-04-24),

3. 8916161 - Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins (2014-12-23),

4. 8901070 - Pharmaceutical compositions comprising pore-forming proaerolysin protein (PRX302) (2014-12-02),

Sophiris Bio Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of urological diseases. The company's lead product candidate, PRX302, is in clinical development for the treatment of localized prostate cancer and benign prostatic hyperplasia (BPH). Sophiris Bio is dedicated to improving the lives of patients suffering from these conditions through innovative therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

4 Patents

#211 in Vancouver

#3,379 in Canada

Vancouver, Canada

Sophiris Bio Inc.

Forward Citations = 23

3 inventors:

J Curtis Nickel (2 out of 3 patents)

J Thomas Buckley (1 out of 4 patents)

James Thomas Buckley (1 out of 4 patents)

Please report any incorrect information to support@idiyas.com